92O - Tumor burden and tyrosine kinase inhibitors (TKI) benefit in advanced non-small cell lung cancer (NSCLC) patients with EGFR sensitizing mutations (E...

Date 27 March 2014
Event ELCC 2014
Session Proffered Papers 1 - Advanced disease with tageted agents
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Charlotte Leduc
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors C. Leduc1, N. Moussa2, L. Faivre3, P. Biondani4, J. Pignon5, C. Caramella2, B. Besse4
  • 1Pneumologie, Hopitaux Universitaires de Strasbourg, 67000 - Strasbourg/FR
  • 2Radiologie, Institut Gustave Roussy, Villejuif/FR
  • 3Biostastistique, Institut Gustave Roussy, Villejuif/FR
  • 4Oncologie, Institut Gustave Roussy, Villejuif/FR
  • 5Biostatistique, Institut de Cancérologie Gustave Roussy, Villejuif/FR


EGFRm and ALK+ are eligible to TKI. Predictive factors of response to TKI are poorly known, in particular the impact of the initial tumor burden. The objective of this study is to define if the initial tumor volume impacts TKI benefit in advanced NSCLC with EGFRm or ALK+.